Status:
COMPLETED
LANCGMS - Lantus Continuous Glucose Monitoring Subcutaneous
Lead Sponsor:
Sanofi
Conditions:
Diabetes Mellitus
Eligibility:
All Genders
18-65 years
Phase:
PHASE4
Brief Summary
Comparison of incidence of hypoglycaemic events and glycaemic fluctuations in diabetic patients with basal substitution with NPH insuline versus insuline glargine. Evaluation of HbA1c, FBG (Fasting Bl...
Eligibility Criteria
Inclusion
- Patients with Diabetes Mellitus Type 1 and Diabetes Mellitus Type 2 with HbA1c 6% and more with more than 2 confirmed hypoglycaemic events (glycaemia less than 3,3 mmol/l) during last year
Exclusion
- Diabetic ketoacidosis
- Any other severe disease
- Pregnancy or fertile female without contraception
- Alcohol/drug abuse, selected prohibited concomitant medication
- Nightshift work
Key Trial Info
Start Date :
April 1 2006
Trial Type :
INTERVENTIONAL
End Date :
November 1 2006
Estimated Enrollment :
35 Patients enrolled
Trial Details
Trial ID
NCT00322075
Start Date
April 1 2006
End Date
November 1 2006
Last Update
September 12 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sanofi-Aventis
Prague, Czechia